Ipca Laboratories and BRL Announce Global Licensing Collaboration for Subcutaneous Biologics Delivery Technology
Ipca Laboratories Ltd. (Ipca) and Bhami's Research Laboratory (BRL) have announced a definitive global licensing agreement that grants Ipca access to BRL’s proprietary high-concentration subcutaneous biologics delivery platform. This partnership is designed to support the development and commercialization of multiple monoclonal antibody products aimed at oncology and inflammatory diseases worldwide.The strategic collaboration combines Ipca's established scientific expertise with BRL's novel formulation technology to accelerate the creation of affordable biologics for individuals facing cancer and autoimmune conditions globally, according to Pranay Godha, MD & CEO of Ipca Laboratories.
Surya Pai, CEO & Co-Founder of BRL, stated that the partnership is set to expand the reach of their patented subcutaneous protein delivery platform. "This strategic partnership is designed to make patient care convenient, affordable and safe," he said.
Akhil Shah, Director & CEO of WeTranslate, noted the role of the technology firm, stating, "BRL has built a differentiated formulation technology platform, and Ipca brings the scale, expertise, and global reach required to unlock its full potential."
Deal Snapshot Details
The licensing agreement encompasses worldwide territory and outlines specific roles for both companies in the development process. The core elements of the collaboration include:| Element | Details |
|---|---|
| License Territory | Worldwide |
| Scope | Proof Of concept (POC) development and Formulation Development by BRL, followed by Further Research and Development, Clinical Trials, Commercial Manufacturing & Launch by Ipca. |
| Licensing Fee | BRL will receive a defined milestone fee pertaining to the Technology Transfer. |
| Royalty | BRL will receive Royalty on net sales upon commercialization of the product. |
Company Profiles
Ipca Laboratories Ltd., established in 1949, is a vertically integrated pharmaceutical company with significant strengths in exports, which account for nearly 50% of its income. Ipca manufactures finished dosage forms and active pharmaceutical ingredients (APIs) and has served as a healthcare partner in over 120 countries for more than seven decades. The company focuses heavily on biosimilars/biologicals, emphasizing the development and commercialization of anti-cancer and anti-inflammatory monoclonal antibodies.Bhami Research Laboratory Pvt. Ltd. (BRL), based in Mangalore, is a biotech firm with 12 years of experience, focused on reinventing patient friendly and affordable biologics drug delivery. BRL holds expertise in protein and peptide drug delivery and operates using a licensing model where it out-licenses technology on a molecule specific basis.
WeTranslate, the life sciences business development firm, served as the strategic licensing partner for BRL in executing this collaboration with Ipca Laboratories.
IPCALAB Stock Price Movement
IPCA Laboratories Limited saw its shares slip today as the stock settled at ₹1,583, following a decline of 1.52%. Trading finished on a substantial volume of 131,987 shares after the equity edged down close to the session's low of ₹1,568.60.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.